Affiliation:
1. Institute of Pharmaceutical Research, GLA University, Mathura, 281406, U.P., India
Abstract
Abstract:
Due to the extremely contagious nature of SARS-COV-2, it presents a significant threat to humans
worldwide. A plethora of studies are going on all over the world to discover the drug to fight SARS-COV-2. One
of the most promising targets is RNA-dependent RNA polymerase (RdRp), responsible for viral RNA replication
in host cells. Since RdRp is a viral enzyme with no host cell homologs, it allows the development of selective
SARS-COV-2 RdRp inhibitors. A variety of studies used in silico approaches for virtual screening, molecular
docking, and repurposing of already existing drugs and phytochemicals against SARS-COV-2 RdRp. This review
focuses on collating compounds possessing the potential to inhibit SARS-COV-2 RdRp based on in silico studies
to give medicinal chemists food for thought so that the existing drugs can be repurposed for the control and treatment
of ongoing COVID-19 pandemic after performing in vitro and in vivo experiments.
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmaceutical Science,Biotechnology
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献